| Literature DB >> 27547442 |
Grégory Dubourg1, Jean-Christophe Lagier2, Sophie Hüe3, Mathieu Surenaud4, Dipankar Bachar2, Catherine Robert2, Caroline Michelle2, Isabelle Ravaux5, Saadia Mokhtari6, Matthieu Million7, Andreas Stein5, Philippe Brouqui7, Yves Levy8, Didier Raoult9.
Abstract
OBJECTIVES: Gut microbiota modifications occurring during HIV infection have recently been associated with inflammation and microbial translocation. However, discrepancies between studies justified a comprehensive analysis performed on a large sample size. DESIGN AND METHODS: In a case-control study, next-generation sequencing of the 16S rRNA gene was applied to the faecal microbiota of 31 HIV-infected patients, of whom 18 were treated with antiretroviral treatment (ART), compared with 27 healthy controls. 21 sera samples from HIV-infected patients and 7 sera samples from control participants were used to test the presence of 25 markers of inflammation and/or immune activation.Entities:
Keywords: HIV/AIDS; INFLAMMATION; INTESTINAL BACTERIA; OXIDATIVE STRESS
Year: 2016 PMID: 27547442 PMCID: PMC4985784 DOI: 10.1136/bmjgast-2016-000080
Source DB: PubMed Journal: BMJ Open Gastroenterol ISSN: 2054-4774
Figure 1Shannon indices applied on HIV cases and non-HIV controls. ART, antiretroviral treatment.
Figure 2Cladogram yielding taxa enriched in each case and control group with an LDA score >2.
Figure 3LDA scores of differentially abundant species among cases and controls and their tolerance to oxygen according to the ‘List of Prokaryotes according to their Aerotolerant or Obligate Anaerobic Metabolism’. The LDA scores represent the effect size of each abundant species. Species enriched in each group with an LDA score >2 are considered.
Significant associations found between different analysed markers (translocation markers, T-cell activation markers and chemokines) and specific taxa
| Taxon | Depleted or enriched in HIV | Marker | Marker type | R-Spearman | p Value |
|---|---|---|---|---|---|
| Depleted | IP-10/CXCL10 | Chemokine | −05 047 | 00 062 | |
| sCD27 | T-cell activation | −04 712 | 00 131 | ||
| sCD30 | T-cell activation | −04 131 | 00 289 | ||
| ND | I-FABP | Translocation | 03 992 | 00 353 | |
| IP-10/CXCL10 | Chemokine | 0434 | 0021 | ||
| sCD27 | T-cell activation | 03 821 | 00 492 | ||
| Enterococcaceae | Enriched | MIG/CXCL9 | Chemokine | 04 209 | 00 257 |
| sCD163 | Translocation | 05 348 | 0004 | ||
| sCD27 | T-cell activation | 03 936 | 00 422 | ||
| Enriched | IP-10/CXCL10 | Chemokine | 04 149 | 00 281 | |
| MIG/CXCL9 | Chemokine | 0433 | 00 214 | ||
| sCD163 | Translocation | 04 022 | 00 375 | ||
| sCD27 | T-cell activation | 04 785 | 00 116 | ||
| Depleted | IP-10/CXCL10 | Chemokine | −06 201 | 00 004 | |
| MIG/CXCL9 | Chemokine | −04 505 | 00 161 | ||
| MIP-3a/CCL20 | Chemokine | −03 759 | 00 487 | ||
| sCD14 | Translocation | −04 618 | 00 153 | ||
| sCD27 | T-cell activation | −03 939 | 00 421 | ||
| sCD30 | T-cell activation | −04 822 | 00 094 | ||
| Depleted | IP-10/CXCL10 | Chemokine | −04 302 | 00 223 | |
| MIG/CXCL9 | Chemokine | −03 916 | 00 393 | ||
| sCD163 | Translocation | −04 858 | 00 102 | ||
| Depleted | IP-10/CXCL10 | Chemokine | 05 803 | 00 062 | |
| MIG/CXCL9 | Chemokine | −04 597 | 00 138 | ||
| MIP-3A/CCL20 | Chemokine | −04 209 | 00 257 | ||
| sCD14 | Translocation | −04 815 | 0011 | ||
| sCD27 | T-cell activation | −06 367 | 00 004 | ||
| sCD30 | T-cell activation | −04 476 | 00 169 | ||
| Depleted | IP-10/CXCL10 | Chemokine | −04 419 | 00 185 | |
| MIP-3a/CCL20 | Chemokine | −05 177 | 00 048 | ||
| sCD14 | Translocation | −04 872 | 0,01 | ||
| sCD27 | T-cell activation | −04 311 | 00 248 |